AUS
NZ
UK
CA
USA
IND
Highlights
LungLife AI Inc (LLAI) secures exclusive US licensing and distribution rights for its LungLB test through a deal with Circulogene Theranostics.
An upfront payment is complemented by milestone-linked sums and a guaranteed royalty floor.
Circulogene holds a defined option to acquire the LungLB assets, with net proceeds earmarked for shareholder distribution.
The biotechnology diagnostic sector focuses on developing tools for early disease detection and precision medicine. LungLife AI Inc (LSE:LLAI) operates in this arena, offering non‑invasive solutions designed to improve lung cancer diagnosis through its proprietary LungLB liquid biopsy test.
Terms of the Exclusive Licensing Agreement
LungLife AI Inc entered into an exclusive licensing and distribution pact with Circulogene Theranostics. Under the agreement, Circulogene gains sole rights to commercialize the LungLB test in the United States. The arrangement empowers Circulogene to leverage its existing laboratory network and sales infrastructure to introduce the test to clinical laboratories and healthcare providers nationwide.
Financial and Commercial Structure
The agreement provides LungLife AI Inc with an initial cash receipt, followed by additional payments upon achievement of regulatory milestones and volume thresholds. A royalty structure accompanies these payments, including a defined minimum royalty amount during the initial commercial phase. This structure aims to generate a steady revenue stream as Circulogene deploys its marketing capabilities to drive test adoption across diagnostic centers.
Ownership Option and Shareholder Impact
An integral component of the deal grants Circulogene an option to acquire full ownership of the LungLB test and related intellectual property at a predetermined valuation. Should Circulogene exercise this right, LungLife AI Inc intends to allocate a portion of the proceeds to its shareholders. Such a distribution is structured to reflect the value creation from the transaction and may coincide with a delisting from the London AIM market, pending board approval and regulatory clearance.
Operational Rollout
Circulogene’s laboratory footprint and established relationships with pathology providers form the basis for a phased rollout. Initial deployment will target high‑volume oncology centers, supported by technical training and laboratory accreditation processes. The phased approach aims to validate operational workflows, ensuring quality control and reproducibility before broader expansion into regional labs.
Sector Implications
The agreement underscores a growing trend of cross‑border partnerships in the diagnostic field, where innovative test developers align with established laboratory services to facilitate market entry and scale. Such collaborations can accelerate clinical adoption of novel assays, enhance access to advanced diagnostics, and drive global competitiveness. As diagnostic developers and distribution specialists converge, the industry moves toward integrated solutions capable of addressing complex healthcare challenges without reliance on a single region’s infrastructure.
